Jan. 29 at 3:34 PM
$LENZ okay this makes sense, VIZZ was first to market with the new round of presbyopia eye drop treatments. We now have other companies getting ready for commercial release.
This is both good and bad, will we have the market to ourselves? No, but other companies wouldn’t invest hundreds of millions in developing these drops if they didn’t think the market for it was there and willing to use the product.
Tenpoint Therapeutics Ltd: Announced FDA approval on January 28, 2026, for YUVEZZI (carbachol and brimonidine tartrate), described as the first dual-agent eye drop for presbyopia. Note: Tenpoint has engaged in significant financing and was reported to be preparing for a commercial launch in Q2 2026.
Only thing we can do is wait and see how volume looks for us vs competitors. Challenge being many competitors are not publicly traded companies so their information won’t be as widely available.
